	Scientific and Technical Informa	ation Center	
1 1	SEARCH REQUEST	FORM	
10/11/01	DAVINIUKTON	712 Examiner # :	63
<del></del>	s Full Name:	Number:	
Art Unit: 1652 Ph Results Format Preferred (circle	PAPER DISK E-MAIL	09/355	210
******	*********	<b>食食食食食食食食食食食食食食食食食食食食</b>	*****
Title: Monocylic Compo	ounds with four Bifunctional residu	es having NK-2 antagonist	action
Applicants: GIORGI, R	AFFAELLO; PIRARI, ROSARIO;	•	<u></u>
GIORGI, GABRIELE;	PIRARI, ROSARIA; DI BUGNO, CARLO ALBERTO;	, CIGDIII II, Carrier	·
DANILO; MAGGI,	Critico industria i		
Earliest Priority Date: 2	17/97		ė.
2		;	20
	* * * *		
	dda halaw	STIC	
Applicants are claimi	ng the compounds below	· · · · · · · · · · · · · · · · · · ·	
R1 = phenyl, imidazo	le, or indole		
R2 = phenyl, imidazo			
R3 = hydrogen or alk	cyl or benzyl; or R3 is the side ch	nain of tryptophan or histi	dine
R4 = anything	1 D		
	\rangle		
		,0	
	H	<b>7</b> .	
	<b>b</b>	^	
	u N	) ~p <sup>2</sup>	
,	4	·	
<i>.</i> `	R O		
•			
	1.	/ -0	
	N	, h <sup>n</sup>	
•	$H_{i}$ $I_{I}$ /	Π	
	0 '3	, , , , , , , , , , , , , , , , , , ,	٠.
	K		
********	*********************	******	*****
STAFF USE ONLY	Type of Search	Vendors and Cost	
Searcher: Alex Waclawiw	NA Sequence (#)	STN	Dialog
seardTechnical Info. Speciali CM1 12C14 Tel: 308-44	191	Questel/Orbit	Dr.Link
Searcher Location;	Structure (#)	Lexis/Nexis	Westlaw
Date Searcher Picked Up: 10-15		WWW/Internet	systems (list)
Date Completed: 10-15	Litigation	Other (specify)	

=> fil reg FILE 'REGISTRY' ENTERED AT 10:03:15 ON 15 OCT 2001 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2001 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 14 OCT 2001 HIGHEST RN 362009-74-3 DICTIONARY FILE UPDATES: 14 OCT 2001 HIGHEST RN 362009-74-3

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER see HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details: http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> d his 11-17

(FILE 'HCAPLUS' ENTERED AT 09:58:10 ON 15 OCT 2001)
DEL HIS Y

FILE 'REGISTRY' ENTERED AT 09:59:07 ON 15 OCT 2001 ACT LUKTON2/A

```
L1 STR
L2 STR
L3 ( 155) SEA FILE=REGISTRY SSS FUL L2
L4 11 SEA FILE=REGISTRY SUB=L3 SSS FUL L1
L5 1 S L4 AND CAOLD/LC - | New York CAOLD
L6 1 S L4 AND USPATFULL/LC
L7 0 S L6 NOT (CA OR CAPLUS)/LC
```

=> d que stat 14 L1 STR

VAR G1=22/23/24 NODE ATTRIBUTES: DEFAULT MLEVEL IS ATOM MLEVEL IS CLASS AT 12 13 GGCAT IS MCY UNS AT 22


```
IS MCY
                   AT
                        23
               UNS
GGCAT
       IS PCY
               UNS
GGCAT
DEFAULT ECLEVEL IS LIMITED
       IS UNLIMITED AT
                        12 13
ECOUNT
       IS E6 C AT 22
ECOUNT
       IS E3 C E1 N AT
                          23
ECOUNT
       IS E8 C E1 N AT
ECOUNT
```

# GRAPH ATTRIBUTES:

RSPEC I

NUMBER OF NODES IS 23

STEREO ATTRIBUTES: NONE STR L2



## NODE ATTRIBUTES: DEFAULT MLEVEL IS ATOM MLEVEL IS CLASS AT 12 13 DEFAULT ECLEVEL IS LIMITED ECOUNT IS UNLIMITED AT 12 13

GRAPH ATTRIBUTES:

RSPEC I

NUMBER OF NODES IS 18

STEREO ATTRIBUTES: NONE

155)SEA FILE=REGISTRY SSS FUL L2 L3

11 SEA FILE=REGISTRY SUB=L3 SSS FUL L1 L4

11 ANSWERS 155 ITERATIONS 100.0% PROCESSED

SEARCH TIME: 00.00.01

## => d 15 ide can

ANSWER 1 OF 1 REGISTRY COPYRIGHT 2001 ACS L5

24181-12-2 REGISTRY RN

Cyclo(D-phenylalanyl-L-phenylalanyl-D-valyl-L-valyl) (9CI) (CA INDEX CN NAME)

OTHER CA INDEX NAMES:

1,4,7,10-Tetraazacyclododecane, cyclic peptide deriv.

Cyclic(D-phenylalanyl-L-phenylalanyl-D-valyl-L-valyl)

OTHER NAMES:

Cyclo(L-phenylalanyl-D-valyl-L-valyl-D-phenylalanyl) CN

Fugisporin CN

Fungisporin CN

PROTEIN SEQUENCE FS

# Lukton 09/355,210

1412-12-0 DR

C28 H36 N4 O4

BEILSTEIN\*, BIOSIS, CA, CAOLD, CAPLUS, CSCHEM, NAPRALERT, MF STN Files: LC

(\*File contains numerically searchable property data)

$$\begin{array}{c|c} CH_2-Ph \\ O & H \\ \hline O & N \\ Ph-CH_2 & N \\ H & Pr-i \\ O & \end{array}$$

4 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

4 REFERENCES IN FILE CAPLUS (1967 TO DATE)

2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

1: 133:340213 REFERENCE

REFERENCE 93:6071 2:

88:23373 3: REFERENCE

71:124896 REFERENCE 4:

=> fil hcaplus FILE 'HCAPLUS' ENTERED AT 10:04:01 ON 15 OCT 2001 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE COVERS 1947 - 15 Oct 2001 VOL 135 ISS 17 FILE LAST UPDATED: 14 Oct 2001 (20011014/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

HCAplus now provides online access to patents and literature covered in CA from 1947 to the present. On April 22, 2001, bibliographic information and abstracts were added for over 2.2 million references published in CA from 1947 to 1966.

'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE

Lukton 09/355,210 (FILE 'HCAPLUS' ENTERED AT 09:59:39 ON 15 OCT 2001) ·12 S L4 L8 => d .ca hitstr 18 1-12 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2001 ACS 2001:10082 HCAPLUS ACCESSION NUMBER: 134:80834 DOCUMENT NUMBER: Cyclic peptides and methods for modulating cell TITLE: adhesion Blaschuk, Orest W.; Gour, Barbara J. INVENTOR(S): McGill University, Can. PATENT ASSIGNEE(S): U.S., 80 pp., Cont.-in-part of U.S. 6,031,072. SOURCE: CODEN: USXXAM Patent DOCUMENT TYPE: English LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION: APPLICATION NO. DATE KIND DATE PATENT NO. \_\_\_\_\_ \_\_\_\_\_ 19971223 US 1997-996679 20010102 В1 US 6169071 US 1997-893534 19970711 20000229 Α US 6031072 US 1998-115395 19980714 20010327 В1 US 6207639 19981223 W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG WO 1998-CA1207 19990708 WO 9933875 AU 1999-18664 A1 19990719 AU 9918664 P 19960712 US 1996-21612 PRIORITY APPLN. INFO.: A2 19970711 US 1997-893534 A2 19971223 US 1997-996679 W 19981223 WO 1998-CA1207 Cyclic peptides and compns. comprising them are provided. The cyclic AB peptides comprise a cadherin cell adhesion recognition sequence HAV. Methods for using the peptides and compns. for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided. ICM A61K038-00 IC ICS A61K038-12 514004000 NCL 1-12 (Pharmacology) CC Section cross-reference(s): 63 4248-64-0 27686-49-3 110590-64-2 113326-33-3 143304-79-4 IT222169-83-7 222169-86-0 202528-03-8 202528-15-2 170032-25-4 229971-67-9 229971-65-7 229971-61-3 229971-64-6 229971-60-2 229971-78-2 231282-25-0 229971-72-6 229971-70-4 229971-68-0 317320-05-1 317320-04-0 317320-03-9 313052-61-8 250268-78-1 317320-10-8 317320-09-5 317320-08-4 317320-07-3 317320-06-2 317320-15-3 317320-14-2 317320-13-1 317320-12-0 317320-11-9 317320-19-7 317320-20-0 317320-18-6 317320-17-5 317320-16-4 317320-25-5 317320-23-3 317320-24-4 317320-22-2 317320-21-1 RL: PRP (Properties) (unclaimed sequence; cyclic peptides and methods for modulating cell adhesion) 317320-20-0 IT RL: PRP (Properties) (unclaimed sequence; cyclic peptides and methods for modulating cell adhesion)

317320-20-0 HCAPLUS

RN Cyclo(glycylglycyl-L-tryptophyl-L-tryptophyl) (9CI) (CA INDEX NAME) CN

Absolute stereochemistry.

REFERENCE COUNT:

REFERENCE(S):

(1) Alexander; Journal of Cellular Physiology 1993, V156, P610 HCAPLUS

(2) Ali; J Med Chem 1994, V37(6), P769 HCAPLUS

(3) Anon; EP 406428 B1 1991 HCAPLUS (4) Anon; WO 9104745 1991 HCAPLUS

(5) Anon; WO 9208731 1992 HCAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 2 OF 12 HCAPLUS COPYRIGHT 2001 ACS 2000:894569 HCAPLUS

ACCESSION NUMBER: DOCUMENT NUMBER:

134:237780

TITLE:

SOURCE:

An evaluation of a novel safety catch linker for

development of cyclic peptide libraries

Bourne, G. T.; McGeary, R. P.; Golding, S. W.; AUTHOR(S):

Meutermans, W. D. F.; Alewood, P. F.; Smythe, M. L. Centre for Drug Design and Development, University of

CORPORATE SOURCE:

Oueensland, Brisbane, 4072, Australia

Pept. New Millennium, Proc. Am. Pept. Symp., 16th (2000), Meeting Date 1999, 98-99. Editor(s): Fields, Gregg B.; Tam, James P.; Barany, George. Kluwer

Academic Publishers: Dordrecht, Neth.

CODEN: 69ATHX

DOCUMENT TYPE:

Conference

English LANGUAGE:

A symposium on the authors' work using the 'safety-catch' linker approach AΒ to synthesis of cyclic peptides.

34-3 (Amino Acids, Peptides, and Proteins) CC 329966-14-5P

329966-10-1P 329966-12-3P ΙT

RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of cyclic peptides using safety-catch linker)

329966-10-1P 329966-12-3P ΙT

RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn. of cyclic peptides using safety-catch linker)

329966-10-1 HCAPLUS RN

Cyclo(L-arginyl-O-.beta.-alanyl-L-threonyl-L-phenylalanyl-D-tryptophyl) CN

#### (9CI) (CA INDEX NAME)

Absolute stereochemistry.

329966-12-3 HCAPLUS RN Cyclo(L-arginyl-O-.beta.-alanyl-L-threonyl-L-phenylalanyl-L-tryptophyl) CN (9CI) (CA INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT: REFERENCE(S):

- (1) Bourne, G; J Org Chem 1999, V64, P3095 HCAPLUS
- (2) Flanigan, E; PhD Dissertation, Washington University 1971
- (3) Holmes, C; J Org Chem 1997, V62, P2370 HCAPLUS
- (4) Jensen, K; J Am Chem Soc 1998, V120, P5441 HCAPLUS

HCAPLUS COPYRIGHT 2001 ACS ANSWER 3 OF 12 2000:772490 HCAPLUS ACCESSION NUMBER: 133:340213

DOCUMENT NUMBER:

TITLE:

Antibody conjugates for delivery of antimicrobial

toxins

INVENTOR(S):

Carlyle, Wenda C.

PATENT ASSIGNEE(S):

St. Jude Medical, Inc., USA

SOURCE:

PCT Int. Appl., 63 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent English

LANGUAGE:

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

APPLICATION NO. DATE DATE KIND PATENT NO. \_\_\_\_\_ -----\_\_\_\_\_ \_\_\_ WO 2000-US8389 20000330 A2 20001102 WO 2000064487

W: BR, JP, ZA

RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

PRIORITY APPLN. INFO.:

US 1999-298638 · A 19990423

An antimicrobial conjugate (100, 120, 154) can be formed that includes an antibody (100, 122) or ligand bonded to an antimicrobial agent (106, 124). The antibody (102, 122, 154) or ligand has an affinity for microbial antigens or receptors. The antimicrobial conjugate  $(\bar{1}00, 120, 154)$  can be used alone or assocd. with biocompatible material (152) incorporated into a medical device (150). An antimicrobial conjugate (100, 120, 154) can be placed in contact with a soln. to eliminate viable microorganisms from the soln. In particular, the antimicrobial conjugate (100, 120, 154) can be used to reduce the risk of infection assocd. with the contact of a medical device with patient's bodily fluids or tissues.

ICM A61K047-48 IC

63-5 (Pharmaceuticals) CC

Section cross-reference(s): 1, 15

56-75-7D, Chloramphenicol, antibody conjugates 57-92-1D, Streptomycin, ΙT antibody conjugates 60-54-8D, Tetracycline, antibody conjugates 61-33-6D, antibody conjugates 113-73-5D, Gramicidin S, antibody conjugates 114-07-8D, Erythromycin, antibody conjugates 1402-38-6D, Actinomycin, antibody conjugates 1404-90-6D, Vancomycin, antibody conjugates 1405-87-4D, Bacitracin, antibody conjugates 1406-11-7D, 2001-95-8D, Valinomycin, antibody Polymyxin, antibody conjugates conjugates 8011-61-8D, Tyrocidine, antibody conjugates 11140-67-3D, Syringomycin, antibody Circulin, antibody conjugates 18524-67-9D, Mycobacillin, antibody conjugates conjugates Phosphonomycin, antibody conjugates 24181-12-2D, Fungisporin, antibody conjugates 53571-13-4D, Malformin, antibody conjugates 67995-63-5D, Pardaxin, antibody conjugates 73590-58-6D, Omeprazole, 103577-45-3D, Lansoprazole, antibody conjugates antibody conjugates RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(antibody conjugates for delivery of antimicrobial toxins)

24181-12-2D, Fungisporin, antibody conjugates IT

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(antibody conjugates for delivery of antimicrobial toxins)

24181-12-2 HCAPLUS RN

Cyclo(D-phenylalanyl-L-phenylalanyl-D-valyl-L-valyl) (9CI) (CA INDEX CN

$$\begin{array}{c|c} CH_2-Ph \\ O & H \\ N & N \end{array}$$

$$Ph-CH_2 & H \\ N & Pr-i \\ O & Pr-i \end{array}$$

ANSWER 4 OF 12 HCAPLUS COPYRIGHT 2001 ACS L8

ACCESSION NUMBER:

2000:288753 HCAPLUS

DOCUMENT NUMBER: TITLE:

133:164306 Cyclic tetrapeptide hydroxamic acids related to

AUTHOR(S):

trapoxin B inhibit histone deacetylase Nishino, Norikazu; Tomizaki, Kin-Ya; Mimoto, Tsutomu;

Komatsu, Yasuhiko; Kim, Young Bae; Yoshida, Minoru Institute for Fundamental Research of Organic

CORPORATE SOURCE:

Chemistry, Kyushu University, Fukuoka, 812-8581, Japan

Pept. 1998, Proc. Eur. Pept. Symp., 25th (1999),

SOURCE:

Meeting Date 1998, 832-833. Editor(s): Bajusz, Sandor; Hudecz, Ferenc. Akademiai Kiado: Budapest,

Hung.

CODEN: 68WKAY Conference

DOCUMENT TYPE:

English

LANGUAGE: A symposium report. Trapoxin B analogs, cyclic tetrapeptides contg. .alpha.-aminosuberyl, .alpha.-aminoazelayl, and .alpha.-aminopimelyl .omega.-hydroxamic acids, were prepd. and tested for inhibition of histone deacetylase.

34-3 (Amino Acids, Peptides, and Proteins) CC

Section cross-reference(s): 7

221186-42-1P 221186-39**-**6P 133155-90-5DP, Trapoxin B, analogs IT 221186-56-7P 221186-58-9P **221186-59-0P** 221186-43-2P RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (prepn. of trapoxin B-related cyclic tetrapeptide hydroxamic acids as histone deacetylase inhibitors)

221186-59-0P ΙT

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (prepn. of trapoxin B-related cyclic tetrapeptide hydroxamic acids as histone deacetylase inhibitors)

221186-59-0 HCAPLUS

RN Cyclo[N-methylglycyl-(2S)-2-amino-8-(hydroxyamino)-8-oxooctanoyl-L-CN phenylalanyl-L-phenylalanyl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT: REFERENCE(S):

SOURCE:

(1) Itazaki, H; J Antibiotics 1990, V43, P1524 HCAPLUS (2) Kijima, M; J Biol Chem 1993, V268, P22429 HCAPLUS

(3) Nishino, N; Biochemistry 1978, V17, P2846 HCAPLUS

(4) Nishino, N; Chem Pharm Bull 1996, V44, P212

(6) Yoshida, M; J Biol Chem 1990, V265, P17174 HCAPLUS HCAPLUS ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 5 OF 12 HCAPLUS COPYRIGHT 2001 ACS

1999:353256 HCAPLUS ACCESSION NUMBER:

131:130252

Histone deacetylase inhibitors based on trapoxin B DOCUMENT NUMBER: Tomizaki, Kin-Ya; Kato, Tamaki; Nishino, Norikazu; TITLE:

AUTHOR(S):

Yoshida, Minoru; Komatsu, Yasuhiko

Department of Applied Chemistry, Faculty of CORPORATE SOURCE:

Engineering, Kyushu Institute of Technology,

Kitakyushu, 804-8550, Japan

Pept. Sci. (1999), Volume Date 1998, 35th, 181-184

CODEN: PSCIFQ; ISSN: 1344-7661 Protein Research Foundation

PUBLISHER: Journal DOCUMENT TYPE:

English LANGUAGE:

A symposium report. Trapoxin B is a cyclic tetrapeptide contg. a unique amino acid, (2S,9S)-2-amino-8-oxo-9,10-epoxydecanoic acid (L-Aoe), whose epoxyketone moiety is supposed to react with mammalian histone deacetylase. The authors synthesized a trapoxin B analog, in which L-Aoe is replaced with L-aminosuberic hydroxamic acid [Asu(NHOH)]. The analog strongly inhibited a histone deacetylase from mouse B16/BL6 cells. Furthermore, the positions of D-amino acids in the trapoxin B hydroxamic acid analog were changed. In addn. to L-L-L-D-form [contg. L-Asu(NHOH)], L-L-D-L-, L-D-L-L, and L-D-L-D-isomers were synthesized. The L-D-L-Land L-D-L-D-isomers exhibited high inhibitory activity, while L-L-D-L-isomer was inactive.

34-3 (Amino Acids, Peptides, and Proteins) CC

Section cross-reference(s): 7

133155-90-5D, Trapoxin B, analogs contg. 58880-19-6, Trichostatin A ΙT 221186-42-1 221186-39-6

aminosuberic hydroxamic acid deriv. 221186-58-9 221186-59-0 221186-57-8 221186-56-7 221186-43-2

234429-77-7

221186-62-5 **234429-76-6** RL: BAC (Biological activity or effector, except adverse); BIOL

(Biological study) (prepn. of hydroxamic analogs of trapoxin B as inhibitors of histone deacetylase)

221186-59-0 234429-76-6 IT

RL: BAC (Biological activity or effector, except adverse); BIOL

(prepn. of hydroxamic analogs of trapoxin B as inhibitors of histone (Biological study) deacetylase)

221186-59-0 HCAPLUS RN

Cyclo[N-methylglycyl-(2S)-2-amino-8-(hydroxyamino)-8-oxooctanoyl-L-CN phenylalanyl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

234429-76-6 HCAPLUS RN

Cyclo[N-methylglycyl-(2S)-2-amino-8-(hydroxymethyl)-8-oxooctanoyl-D-CN phenylalanyl-L-phenylalanyl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT: REFERENCE(S):

(1) Itazaki, H; J Antibiotics 1990, V43, P1524 HCAPLUS

(2) Jacquier, R; Tetrahedron Lett 1984, V25, P5525 **HCAPLUS** 

(3) Kawai, M; Biochem Biophys Res Commun 1983, V111, P398 HCAPLUS

(4) Kijima, M; J Biol Chem 1993, V268, P22429 HCAPLUS

(5) Nishino, N; Chem Pharm Bull 1996, V44, P212

ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 6 OF 12 HCAPLUS COPYRIGHT 2001 ACS 1999:184270 HCAPLUS ACCESSION NUMBER:

130:237885

DOCUMENT NUMBER: Preparation of novel cyclic tetrapeptide derivatives as histone deacetylase inhibitors and MHC class-1 TITLE:

molecule expression promoters

Nishino, Norikazu; Yoshida, Minoru; Horinouchi, INVENTOR(S):

Sueharu; Komatsu, Yasuhiko; Mimoto, Tsutomu

Japan Energy Corporation, Japan PATENT ASSIGNEE(S):

PCT Int. Appl., 97 pp. SOURCE: CODEN: PIXXD2

Patent DOCUMENT TYPE: Japanese LANGUAGE:

FAMILY ACC. NUM. COUNT:

### PATENT INFORMATION:

```
APPLICATION NO.
                                                          DATE
                    KIND DATE
    PATENT NO.
                                         _____
                    ____
                                                          19980901
                                         WO 1998-JP3893
                     A1
                          19990311
    WO 9911659
        W: AU, CA, JP, KR, NO, NZ, US
        RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
                                                          19980901
                                         AU 1998-88885
    AU 9888885
                           19990322
                      Α1
                           20010412
    AU 732299
                      B2
                                                          19980901
                                         EP 1998-940649
                           20000621
    EP 1010705
        R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
                     Α1
            IE, FI
                                                          19980902
                                          ZA 1998-8023
                           19990302
    ZA 9808023
                      Α
                                         NO 2000-1045
                                                          20000301
                           20000427
                     Α
    NO 2000001045
                                                          19970902
                                       JP 1997-237481 A
PRIORITY APPLN. INFO.:
                                                       Α
                                       JP 1998-63270
                                                          19980313
                                                      W 19980901
                                       WO 1998-JP3893
```

MARPAT 130:237885

OTHER SOURCE(S): Claimed are cyclic tetrapeptide derivs. represented by general formula (I) or pharmaceutically acceptable salts thereof and cyclic tetrapeptide compds. analogous thereto [wherein R11, R12, R21 and R22 represent each hydrogen or a monovalent group selected from linear or branched C1-6 alkyl, benzyl, 4-methoxybenzyl, 3-indolylmethyl, (N-methoxy-3indolyl) methyl, (N-formyl-3-indolyl) methyl, etc.; R3 represents a divalent group selected from divalent linear C3-4 hydrocarbyl optionally having a branched chain added thereto or optionally substituted by a heteroatom; and R4 represents a divalent group derived from divalent linear C4-6 hydrocarbyl optionally having a branched chain added thereto]. Also claimed are histone deacetylase inhibitors, MHC class-1 mol. expression promoters, and anticancer agents contg. these cyclic tetrapeptide derivs. as the active ingredient. The hydroxamic acid side chain is responsible for the activity of MHC class-1 mol. expression promotion. These cyclotetrapeptides markedly promote the removal of cancer cells by immune cells using promotion of MHC-1 mol. expression, since they also inhibit cell proliferation and cell cycles, thereby the expansion of cancer tissues, based on histone deacetylase inhibition. They are much more reduced in undesirable side-effects such as cell proliferation inhibition and cell cycle inhibition against normal cells as compared to irreversible enzyme inhibitors, since histone deacetylase enzyme inhibition is reversible. Thus, the title peptide (II) was prepd. via deprotection of Boc-Asu(OBzl)-D-Phe-Leu-DL-Pip-OtBu (Asu = .alpha.-aminosuberic acid residue, Pip = 2-carboxypiperidine residue) (prepn. given), cyclization, and conversion of the side-chain carboxylic acid into hydroxyaminocarbonyl group. II at 3.86 nM in vitro promoted twice the expression of MHC-1 mol. in mouse melanoma B16/BL6 cells as compared to 3.35 nM for trichostatin A and showed IC50 of 12.3 nM against the proliferation of B16/BL6 cells as compared to 14.3 nM for trichostatin A.

ICM C07K005-12 IC

ICS A61K038-12 34-3 (Amino Acids, Peptides, and Proteins) CC

Section cross-reference(s): 1

221186-45-4P 221186-44-3P 221186-43-2P 221186-42-1P 221186-39-6P IT 221186-50-1P 221186-48-7P 221186-49-8P 221186-47**-**6P 221186-46-5P 221186-55-6P 221186-54-5P 221186-53-4P 221186-52-3P 221186-51-2P 221186-58-9P **221186-59-0P** 221186-57-8P 221186-56-7P 221186-65-8P 221186-64-7P 221186-62-5P 221186-61-4P 221186-60-3P 221186-69-2P 221186-70-5P 221186-68-1P 221186-67-0P 221186-66**-**9P 221186-75-0P 221186-74-9P 221186-72-7P 221186-73-8P 221186-71**-**6P 221186-77-2P 221186-76-1P RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic

preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of novel cyclic tetrapeptide derivs. as histone deacetylase inhibitors and MHC class-1 mol. expression promoters and anticancer agents)

221186-59-0P IT

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of novel cyclic tetrapeptide derivs. as histone deacetylase inhibitors and MHC class-1 mol. expression promoters and anticancer agents)

221186-59-0 HCAPLUS RN

Cyclo[N-methylglycyl-(2S)-2-amino-8-(hydroxyamino)-8-oxooctanoyl-L-CN phenylalanyl-L-phenylalanyl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT:

REFERENCE(S):

(1) Bernardi, E; Peptides 1993, V14(6), P1091 HCAPLUS

(2) Kijima, M; J Biol Chem 1993, V268(30), P22429

HCAPLUS

ANSWER 7 OF 12 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER:

1995:85675 HCAPLUS

DOCUMENT NUMBER:

122:131132

TITLE:

Cyclic peptides manufacture with Flexibacter

INVENTOR(S):

Teramura, Kyoko; Yasumuro, Kenichi; Suzuki, Yasuto; Shibazaki, Mitsuji; Abe, Kenji; Imai, Yoshimitsu;

Suzuki, Kenichi

PATENT ASSIGNEE(S):

Yamanouchi Pharma Co., Ltd., Japan

SOURCE:

Jpn. Kokai Tokkyo Koho, 14 pp.

CODEN: JKXXAF

DOCUMENT TYPE:

Patent

LANGUAGE:

Japanese

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
TP 06172385	A2	19940621	JP 1992-351725	19921208

MARPAT 122:131132 OTHER SOURCE(S):

Cyclic peptides (I, R1 = benzylcarbonyl, isovaleryl; R2 and R3 are OH individually or together as carbonyl) and II are manufd. by culturing Flexibacter sp. I and II are inhibitors for esterase of leukocytes and are useful for treatment of lung diseases such as ARDS.

C07K005-12 IC ICM A61K037-02; C07K005-08; C12P021-02 ICS

ICA C12N009-99

ICI C12P021-02, C12R001-01

16-2 (Fermentation and Bioindustrial Chemistry) CC

157951-38-7P 157951-39-8P, Cyclo(leucyltryptophyltryptophylseryl IT

157951-40-1P

RL: PREP (Preparation)

(manuf of cyclic peptide, with Flexibacter for leukocyte esterase inhibitor)

157951-39-8P, Cyclo(leucyltryptophyltryptophylseryl) ΙT

RL: PREP (Preparation)

(manuf of cyclic peptide, with Flexibacter for leukocyte esterase inhibitor)

157951-39-8 HCAPLUS RN

Cyclo(leucyltryptophyltryptophylseryl) (9CI) (CA INDEX NAME) CN

ANSWER 8 OF 12 HCAPLUS COPYRIGHT 2001 ACS

1994:164873 HCAPLUS ACCESSION NUMBER:

120:164873 DOCUMENT NUMBER:

How to perform small peptide cyclizations

Cavelier-Frontin, Florine; Achmad, Sadijah; Verducci, TITLE: AUTHOR(S):

Jean; Jacquier, Robert; Pepe, Gerard

URA-CNRS 468 Aminoacides et peptides, Universite Montpellier II, Place Eugene Bataillon, Montpellier, CORPORATE SOURCE:

34095/05, Fr.

THEOCHEM (1993), 105(1-3), 125-30 SOURCE:

CODEN: THEODJ; ISSN: 0166-1280

Journal DOCUMENT TYPE:

English Small cyclopeptides of four to six residues are very interesting for their LANGUAGE: Unfortunately, the synthesis of the linear precursor is biol. properties. generally fastidious and the cyclization often occurs in low yields. Mol. modeling used through the GENMOL program is a powerful tool for predicting the best precursor, as was shown in a previous paper about five tetrapeptides. However, sometimes all the linear precursors of a cyclopeptide can be unfavorable for cyclization when no structural feature (N-Me amino acid, Pro, D-amino acid) is present in the peptide. This led to the development of a method using a reversible chem. modification of the peptide main chain in order to favor the cisoid conformation able to cyclize easily. Tetra(phenylalanine) was used as a model, with the tert-butyloxycarbonyl (Boc) group as substituent on the main-chain nitrogen atoms. The cyclization yield increases from <1% to 27% after this chem. modification and cleavage of the Boc groups. Mol. modeling on such mols. shows that this yield increase is due to a preferred conformation having the terminal functions close together induced by the Boc substituents.

34-3 (Amino Acids, Peptides, and Proteins) CC Section cross-reference(s): 22

17528-16-4, L-Phenylalanine, N-[N-(N-L-phenylalanyl-L-phenylalanyl)-L-IT 153586-84-6 **153586-85-7** phenylalanyl] - methyl ester RL: RCT (Reactant)

(cyclization of, effect of temporary protection on conformations for)

153586-85-7 IT

RL: RCT (Reactant)

(cyclization of, effect of temporary protection on conformations for)

153586-85-7 HCAPLUS

RN Cyclo[L-phenylalanyl-N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl-N-CN [(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl-N-[(1,1dimethylethoxy)carbonyl]-L-phenylalanyl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

ANSWER 9 OF 12 HCAPLUS COPYRIGHT 2001 ACS 1980:406071 HCAPLUS

ACCESSION NUMBER:

93:6071 DOCUMENT NUMBER:

Gushing-inducing peptides in beer produced by TITLE:

Penicillium chrysogenum

Kitabatake, Katsuaki; Fukushima, Shuji; Kawasaki, AUTHOR(S):

Ichiro; Amaha, Mikio

Cent. Res. Lab., Asahi Brew. Ltd., Tokyo, 143, Japan CORPORATE SOURCE:

Pept. Chem. (1980), Volume Date 1979, 17th, 7-12

SOURCE: CODEN: PECHDP

DOCUMENT TYPE: Journal English LANGUAGE:

A cyclic peptide that induced gushing in bottled beer was isolated from culture filtrates of P. chrysogenum. It was identified as cyclo-D-Val-L-Val-D-Phe-L-Phe (I) [24181-12-2]. Another factor inducing beer gushing was isolated that was a mixt. of I and other tetrapeptides contg. valine, phenylalanine, and tyrosine. The gushing caused by several natural and synthetic peptides was examd. and the results are tabulated. Cyclic structure was important; little or no gushing was induced by linear peptides.

16-3 (Fermentations) CC

Section cross-reference(s): 34

24181-12-2 TΤ

RL: BIOL (Biological study)

(beer gushing caused by, from Penicillium chrysogenum)

70274-72-5 68671-23-8 64763-82-2 38184-76-8 26048-05-5 2001-95-8 IT 73787-53-8 70274-76-9 **73787-51-6** 73787-52-7 70274-74-7 73787-54-9 **73804-19-0** 

RL: BIOL (Biological study)

(beer gushing induction by)

24181-12-2 ΙT

RL: BIOL (Biological study)

(beer gushing caused by, from Penicillium chrysogenum)

24181-12-2 HCAPLUS RN

Cyclo(D-phenylalanyl-L-phenylalanyl-D-valyl-L-valyl) (9CI) (CA INDEX CN

$$\begin{array}{c|c} CH_2-Ph \\ \hline \\ O & H \\ \hline \\ Ph-CH_2 & N \\ \hline \\ N & N \\ \hline \\ N & O \\ \end{array}$$

73787-51-6 73804-19-0 IT

RL: BIOL (Biological study) (beer gushing induction by)

73787-51-6 HCAPLUS RN

Cyclo(D-phenylalanyl-L-tyrosyl-D-valyl-L-valyl) (9CI) (CA INDEX NAME) CN

$$\begin{array}{c|c} CH_2-Ph \\ O & H \\ \hline O & H \\ \hline O & N \\ \hline CH_2 \\ \hline O & OH \\ \hline O & OH \\ \hline O & OH \\ \hline \end{array}$$

73804-19-0 HCAPLUS RN

Cyclo(L-phenylalanyl-D-phenylalanyl-L-valyl-D-valyl) (9CI) (CA INDEX CN NAME)

$$\begin{array}{c|c} & CH_2-Ph \\ & & O \\ & & & O \\ Ph-CH_2 & & & \\ & & & \\ & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & & \\ & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ &$$

HCAPLUS COPYRIGHT 2001 ACS ANSWER 10 OF 12

ACCESSION NUMBER:

1978:23373 HCAPLUS

DOCUMENT NUMBER:

88:23373

TITLE:

Synthesis of biologically active cyclic peptides and

depsipeptides by the phosphite method

AUTHOR(S):

Rothe, M.; Kreiss, W.

CORPORATE SOURCE:

SOURCE:

Org.-Chem. Inst., Univ. Mainz, Mainz, Ger. Pept., Proc. Eur. Pept. Symp., 14th (1976), 71-8. Editor(s): Loffet, Albert. Editions Univ. Bruxelles:

Brussels, Belg. CODEN: 36PZAV

DOCUMENT TYPE:

Conference

English LANGUAGE:

H-(Val-D-Hyv-D-Val-L-Lac)n-OH [I; Hyv = OCH(CHMe2)CO, Lac = OCHMeCO, n = OCHMeCO) AΒ 3] was cyclized by the phosphite method in toluene or diethyl phosphite (DEP) to give cyclo(Val-D-Hyv-D-Val-L-Lac)m (II; m = 3) (valinomycin) in 24 or 56% yields, whereas I (n = 1, 2) were cyclized by the phosphite method in toluene or DEP to give II (m = 1-4, 6). II (m = 1) had a very stable crystal lattice and its IR spectrum gave no indication of cis peptide bonds. Antamanide (III) was prepd. by the phosphite-mediated cyclization of H-Phe-Phe-Val-Pro-Pro-Ala-Phe-Phe-Pro-Pro-OH (IV) or H-Pro-Ala-Phe-Phe-Pro-Phe-Phe-Val-Pro (V); IV always gave higher yields than V. Protected gramicidin S cyclo[Val-Orn(Pht)-Leu-D-Phe-Pro]p (VI, Pht = phthalyl, p = 2], protected semigramicidin S VI (p = 1), and cyclo(D-Phe-Phe-D-Val-Val) (fungisporin) were also prepd. by the phosphite method.

34-3 (Synthesis of Amino Acids, Peptides, and Proteins) CC

16898-32-1P 20696-06-4P 2001-95-8P 14410-23-2P 14735-43-4P ΙT 65034-96-0P 61491-09-6P 52611-33-3P 24181-12-2P

RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of, by phosphite method)

ΙT 24181-12-2P

RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of, by phosphite method)

24181-12-2 HCAPLUS RN

Cyclo(D-phenylalanyl-L-phenylalanyl-D-valyl-L-valyl) (9CI) (CA INDEX CN NAME)

$$\begin{array}{c|c} & CH_2-Ph \\ & O & H \\ \hline N & O & H \\ Ph-CH_2 & N & N \\ & N & Pr-i \\ & O & \\ \end{array}$$

ANSWER 11 OF 12 HCAPLUS COPYRIGHT 2001 ACS

1972:443496 HCAPLUS ACCESSION NUMBER:

DOCUMENT NUMBER: 77:43496

Cyclic peptide analogs of gastrin TITLE:

Tritsch, G. L.; Sachatello, C. R.; Grahl-Nielsen, O.; AUTHOR(S):

Moriarty, C. L.; Sedwick, J.

Roswell Park Mem. Inst., New York State Dep. Health, CORPORATE SOURCE:

Buffalo, N. Y., USA

J. Med. (Basel) (1971), 2(2), 82-5 SOURCE: CODEN: JNMDBO

Journal DOCUMENT TYPE: English LANGUAGE:

Cyclic forms of 2 biol. active gastrin peptide analogs were synthesized and shown to be devoid of secretagogue activity on i.v. administration to dogs. In addn., the cyclic peptides were unable to inhibit the activity of an active secretagogue. The gastrin receptors seem to require not only the proper amino acid sequence but also a particular 3-dimensional conformation of biol. active analogs of gastrin.

2-3 (Hormone Pharmacology) CCIT

37792-56-6 37792-55-5 RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)

(biol. activity of)

ΙT 37792-55-5 RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)

(biol. activity of)

RN 37792-55-5 HCAPLUS

Cyclo(L-.alpha.-aspartyl-L-phenylalanyl-L-tryptophyl-L-methionyl) (9CI) CN (CA INDEX NAME)

Absolute stereochemistry.

HCAPLUS COPYRIGHT 2001 ACS ANSWER 12 OF 12

1969:524896 HCAPLUS ACCESSION NUMBER:

71:124896 DOCUMENT NUMBER:

Synthesis and structure of fungisporin TITLE:

Studer, Rolf O. AUTHOR(S):

Chem. Res. Dep., F. Hoffmann-La Roche and Co. A.-G., CORPORATE SOURCE:

Basel, Switz.

Experientia (1969), 25(9), 899 SOURCE:

CODEN: EXPEAM

DOCUMENT TYPE: Journal English LANGUAGE:

Fungisporin, a cyclooctapeptide, was previously reported as having the AB structure cyclo-(Phe-Val)4. Sequence studies indicated cyclo-(D-Val-L-Val-D-Phe-L-Phe)2. Z-L-Phe-D-Val-L-Val-D-Phe-O-Bu-tert (I) was prepd. by the stepwise elongation using the N-hydroxysuccinimide esters of the corresponding Z-amino acids. When I was treated with F3CCO2H, the tert-BuO group was removed and the resulting Z-tetrapeptide was activated with bis(p-nitrophenyl) sulfite and the Z group removed with HBr-AcOH. The p-nitrophenyl ester was cyclized under high diln. in pyridine to give a product with mol. wt. 482 by mass spectrometry which indicated a cyclic tetrapeptide. Natural fungisporin also has mol. wt. 482. (Z-PhCH2O2C)

34 (Synthesis of Amino Acids, Peptides, and Proteins) CC

IT24181-12-2

RL: PRP (Properties)

(structure of)

IT 24181-12-2

RL: PRP (Properties)

(structure of)

RN 24181-12-2 HCAPLUS

Cyclo(D-phenylalanyl-L-phenylalanyl-D-valyl-L-valyl) (9CI) (CA INDEX CN NAME)

$$\begin{array}{c|c} CH_2-Ph \\ O & H \\ N & N \end{array}$$

$$Ph-CH_2 & N & N \\ H & Pr-i \\ O & Pr-i \end{array}$$

=> fil caold FILE 'CAOLD' ENTERED AT 10:05:44 ON 15 OCT 2001 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966 FILE LAST UPDATED: 01 May 1997 (19970501/UP)

0 S L5.

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> d his 19

(FILE 'CAOLD' ENTERED AT 09:59:53 ON 15 OCT 2001)

L9

Dut no referred in CHOLD but no referred to why there is no referred to this registry number. When Quet a reply from CHS Q'II let you know.

Rex 308-4491